viewZelira Therapeutics Ltd

Zelda Therapeutics strengthens Scientific and Medical Advisory Board with two appointments

Professor David Casarett and Dr Dustin Sulak add clinical expertise and depth to the board.

Scientists in a laboratory
Zelda is developing medicinal cannabis therapies for autism, insomnia and cancer

Zelda Therapeutics Ltd (ASX:ZLD) (OTCBB:ZLDAF) has added clinical expertise and depth to its Scientific and Medical Advisory Board through the appointment of two medicinal cannabis experts.

Professor David Casarett and Dr Dustin Sulak are internationally recognised as key opinion leaders in the clinical use of medicinal cannabis and are both based in the United States.

READ: Zelda Therapeutics attracts new managing director, Dr Richard Hopkins

The appointments support the development of Zelda’s novel medicinal cannabis therapies for autism, insomnia and cancer.

Zelda’s managing director Dr Richard Hopkins said, “We are delighted Dr Casarett and Dr Sulak have agreed to join our Scientific and Medical Advisory Board.

“They bring extensive expertise in the use of medicinal cannabis that will inform our clinical programs for indications including autism, insomnia and cancer.

“Their ability to access US-based patient groups will also support our strategy to bring Zelda-branded products to market.”


Professor Casarett is a leading palliative care physician and researcher at Duke University in North Carolina with a core interest in medicinal cannabis.

Dr Sulak is a high-profile medicinal cannabis practitioner who has treated more than 18,000 patients in the US.

World-class advisory board

Other members of the board are Professor Manuel Guzmán, Dr Cristina Sánchez and Dr Noah Federman.

Professor Guzmán is Full Professor of Biochemistry and Molecular Biology at Madrid’s Complutense University and Dr Sánchez is an Assistant Professor at Complutense University, Madrid, Spain.

Dr Federman is director of the Pediatric Bone and Soft Tissue Sarcoma Program at University of California (Los Angeles), part of the UCLA Sarcoma Program and UCLA’s Jonsson Comprehensive Cancer Centre.

READ: Zelda Therapeutics progresses medicinal cannabis brain cancer research

Zelda is an Australian-based bio-pharmaceutical company focused on developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions.

The company has a two-pronged strategy comprising:

- A human clinical trial program focused on insomnia, autism and eczema with activities in Australia, Chile and the USA.

- A pre-clinical research program examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

Quick facts: Zelira Therapeutics Ltd

Price: 0.05 AUD

Market: ASX
Market Cap: $48.31 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...



Full interview: Zelira Therapeutics releases interim data for Phase II...

Zelira Therapeutics Ltd (ASX:ZLD) managing director Dr Richard Hopkins, chairman Osagie Imasogie and clinical trial principal investigator Professor Peter Eastwood, of the University of Western Australia, update Proactive on results from the company’s Phase II clinical trial of medicinal...

on 21/2/20

2 min read